Rosiglitazone alleviates lipopolysaccharide‑induced inflammation in RAW264.7 cells via inhibition of NF‑κB and in a PPARγ‑dependent manner

Abstract

Rosiglitazone is a synthetic peroxisome proliferator-activated receptor (PPAR)γ agonist widely used for the treatment of type 2 diabetes. Recent studies have demonstrated that rosiglitazone displays anti-inflammatory effects. The present study aimed to investigate whether rosiglitazone alleviates decreases in RAW264.7 cell viability resulting from lipopolysaccharide (LPS)-induced inflammation, as well as exploring the underlying mechanism. A macrophage inflammatory injury model was established by treating RAW264.7 cells with 100 ng/ml LPS. Cells were divided into LPS and rosiglitazone groups with different concentrations. Cell viability was assessed by performing an MTT assay. The expression of inflammatory cytokines was detected by conducting enzyme-linked immunosorbent assays and reverse transcription-quantitative PCR. Nitric oxidesecretion was assessed using the Griess reagent system. The expression levels of key nuclear factor-κB pathway-associated proteins were detected via western blotting. Rosiglitazone alleviated LPS-induced decrease in RAW264.7 cell viability and inhibited inflammatory cytokine expression in a concentration-dependent manner. Rosiglitazone significantly inhibited LPS-induced upregulation of p65 phosphorylation levels and downregulated IκBα expression levels. However, rosiglitazone-mediated inhibitory effects were reversed by PPARγ knockdown. The results of the present study demonstrated that rosiglitazone significantly inhibited LPS-induced inflammatory responses in RAW264.7 macrophage cells, which was dependent on PPARγ activation and NF-κB suppression.

Fucoidan-derived carbon dots against Enterococcus faecalis biofilm and infected dentinal tubules for the treatment of persistent endodontic infections

“…Macrophages respond rapidly after exposure to nanomaterial, and as the first line of defense against bacterial infection, macrophages induced to migrate by the nanomaterial are able to eliminate bacteria [ 75 – 77 ]. Therefore, the effect of FDCDs on macrophage recruitment deserves attention [ 78 , 79 ]. As shown in Fig.…”

Decellularization‐Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair

“…Rosiglitazone, a PPARγ agonist, has been reported to inhibit M1 macrophages polarization and reduce the secretion of inflammatory factors. [ 22 ] It have been demonstrated that ECM from dental tissues could serve as a natural carrier for rosiglitazone. While tendinous ECM differs somewhat from dental ECM in composition, both contain a significant amount of collagen I that serves as a constituent material in many sustained‐release systems.…”

Naringin Exerts Therapeutic Effects on Mice Colitis: A Study Based on Transcriptomics Combined With Functional Experiments

“…All these results suggests that naringin exert treatment effects on colitis through inducing PPAR-γ activation. It has been reported that some PPAR-γ agonists, such as rosiglitazone, pioglitazone, exert inhibitory effects on inflammatory responses ( Nitta et al, 2013 ; Zhou et al, 2021 ). In this study, we aimed to search and identify natural products which may serve as PPAR-γ agonists.…”